| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05513391 2022-000576-19 Details | 2024-01-10 Interventional | 3 | 366 | Vaccines Influenza, Huma… Influenza Immun… | Sponsor decision to prematurely stop the study. This decision was made without any safety
concerns. - | |||
| NCT05020665 2021-000761-33 Details | 2024-01-10 Interventional | 3 | 15 | Cytarabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Nucleophosmin 1… | Termination was due to significant challenges associated with study enrollment in a genetic
subset of fit participants in the front-line acute myeloid leukemia (AML) setting and other
challenges associated with post-COVID impacts. Early termination was due to significant unforeseen challenges associated with global enrollment of participants with genetically-defined, newly diagnosed, AML who are candidates for intensive induction therapy and other challenges associated with post-COVID impacts. | |||
| NCT04396535 Details | 2024-01-10 Interventional | 2 | 10 | Docetaxel Carcinoma, Non-… Lung Neoplasms Advanced Lung N… Stage III Lung … Stage IIIA Lung… Stage IIIB Lung… Stage IIIC Lung… Stage IV Lung C… Stage IVA Lung … Stage IVB Lung … | EMD Serono recommendation based on three other studies that failed to show benefit for
bintrafusp alfa - | |||
| NCT02443545 Details | 2024-01-10 Interventional | 4 | 134 | Deferiprone Anemia Anemia, Sickle … Iron Overload Other Anemias Sickle Cell Dis… | Recommendation by DSMB, which felt that sufficient data had been obtained The trial was terminated early upon recommendation of the Data and Safety Monitoring Board (DSMB), which felt that sufficient information had been obtained. | |||
| NCT01620944 2011-006187-47 Details | 2024-01-10 Interventional | 3 | 3 | Atazanavir Sulf… Emtricitabine Lamivudine Ritonavir Tenofovir HIV | Business objectives have changed - | |||
| NCT03502577 Details | 2024-01-08 Interventional | 1 | 19 | Cyclophosphamid… Fludarabine Gamma Secretase… Multiple Myelom… Neoplasms, Plas… Recurrent Plasm… Refractory Plas… | Closed per SRC Low Accrual Policy - | |||
| NCT05055050 Details | 2024-01-05 Interventional | 1 | - | Imiquimod Urinary Bladder… Bladder Bladder Cancer | Interim Analysis - | |||
| NCT04760288 2020-005269-15 Details | 2024-01-05 Interventional | 3 | 0 | Pralsetinib Carcinoma, Neur… Thyroid Disease… Thyroid Neoplas… Medullary Thyro… | Due to several logistical challenges during start-up which could not be overcome study was
withdrawn. - | |||
| NCT04694586 2019-003721-25 Details | 2024-01-05 Interventional | 2 | - | Ethambutol Isoniazid Pyrazinamide Rifampin Tuberculosis Tuberculosis, P… | Suspended 15th of Nov 2023 due to conditions affecting recruitment process. - | |||
| NCT04270019 Details | 2024-01-05 Interventional | 1/2 | 0 | Polyethylene gl… Lacerations Peripheral Nerv… Wounds and Inju… Nerve Injury Peripheral Nerv… | lack of staff, REB closed the file due to expired renewal - | |||
| NCT04046887 Details | 2024-01-05 Interventional | 1 | 14 | Gemcitabine Paclitaxel Adenocarcinoma Pancreatic Neop… Pancreatic Canc… Pancreatic Duct… | Unable to proceed due to Neulasta difficulties and other complications. - | |||
| NCT04030052 Details | 2024-01-05 Interventional | 3 | 0 | Factor VIII Hemophilia A | The Emi PUPs and Nuwiq ITI study has been closed due to slow enrollment and study site startup. - | |||
| NCT03875911 Details | 2024-01-05 Interventional | 4 | 19 | Mitomycin Mitomycins Glaucoma Glaucoma, Open-… Glaucoma Open-A… Open Angle Glau… | Problems unique to COVID-19, incomplete data due to a high rate of dropout to minimize
non-essential appointments and difficult subject recruitment COVID-19 pandemic occurred during study meaning high rates of patients lost to follow-up, as non-emergent visits were canceled or postponed. This led to early termination which means we had a small number of subjects to analyze, especially those who completed all 12 months of follow-up. By the time pandemic restrictions eased, several other studies had published results on similar trials, making further enrollment unnecessary and further supporting early termination of the study. | |||
| NCT03247413 Details | 2024-01-05 Interventional | 4 | [1 Refs] | 63 | Dexamethasone Neuritis Radiofrequency … | Study has been halted prematurely - | ||
| NCT06188104 Details | 2024-01-03 Interventional | 2/3 | 0 | Acetic Acid Congenital Abno… CIN1 Trichloroacetic… | I have found it is quite difficult to conduct the work without changing some detail in original
protocol. So we would like to re-start the study again with some modification. - | |||
| NCT05124210 Details | 2024-01-03 Interventional | 2 | 8 | Sotrovimab COVID-19 | Decrease in in-vitro neutralization of study drug against circulating SARS-CoV-2 variants - | |||
| NCT04987281 Details | 2024-01-03 Interventional | 2 | 0 | Pharmaceutical … Carcinoma, Non-… Lung Neoplasms Neoplasms Lung Non-Small … Metastatic Mali… Stage I Lung Ca… | 0 ACTUAL Enrollment must have Overall Recruitment - | |||
| NCT03864419 Details | 2024-01-03 Interventional | 1 | 18 | Antibodies Antibodies, Mon… Antineoplastic … Cyclophosphamid… Daunorubicin Doxorubicin Etoposide Immunoglobulins Liposomal doxor… Methotrexate Podophyllotoxin Prednisone Rituximab Vincristine Burkitt Lymphom… Castleman Disea… Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Diffuse Large B… KSHV-associated… | Closed per SRC Low Accrual Policy - | |||
| NCT03517722 2017-001489-53 Details | 2024-01-03 Interventional | 3 | 516 | Ustekinumab Lupus Erythemat… | Study terminated early as a result of the outcome of the pre-planned Interim Analysis Due to study termination, the open-label extension phase didn't reach the planned duration till Week 176. However, participants were assessed for safety up to Week 130 (that is, after study termination) and received study drug up to Week 113. | |||
| NCT00585559 Details | 2024-01-03 Interventional | 3 | - | Acetaminophen Acetylcysteine N-monoacetylcys… Hemorrhage Subarachnoid He… Vasospasm, Intr… Aneurysmal Suba… Cerebral Vasosp… | - - |